EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Belimumab in Systemic Lupus Erythematosus: From B-Cell Biology to Disease Modification

Marc Xipell iD, María Cecilia Garbarino iD, Cristina Serrano Del Castillo, Laura Morantes, Carla Bastida iD, Ignasi Rodríguez-Pintó iD, Jose A Gómez-Puerta iD, Gerard Espinosa iD, Luis F Quintana iD, Ricard Cervera iD

Journal of Clinical Medicine · 21.04.2026 · 15 (8) · 3173

DOI: 10.3390/jcm15083173 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Clinical Medicine, online erschienen am 21.04.2026. Verfasst von Marc Xipell und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology and Renal Transplantation, Hospital Clinic, 08036 Barcelona, Spain. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 104 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Systemic lupus erythematosus (SLE) is a heterogeneous autoimmune disease in which B-cell dysregulation plays a central pathogenic role beyond autoantibody production. Advances in B-cell biology have led to the development of targeted therapies, including inhibition of the B-cell activating factor (BAFF) pathway. Belimumab, a monoclonal antibody that neutralizes soluble BAFF, modulates B-cell survival signals upstream, promoting progressive immunologic remodeling rather than rapid depletion. This review integrates current knowledge on BAFF-dependent B-cell biology with mechanistic, pharmacokinetic, and clinical data to provide a comprehensive framework for understanding belimumab’s effects in SLE and lupus nephritis (LN). Belimumab preferentially reduces transitional and naïve B cells, while memory B cells show a relative transient increase followed by a gradual return to baseline levels, reflecting redistribution rather than expansion, and long-lived plasma cells are largely unaffected. These effects result in progressive remodeling of B-cell compartment dynamics and contribute to broader modulation of adaptive immune amplification pathways. Pharmacokinetic data support a threshold-based model of BAFF neutralization, with exposure influenced by disease-related factors such as proteinuria in LN. Clinical response is primarily determined by baseline disease biology, with greater benefit observed in patients with serologically active disease and less established organ involvement. Across clinical trials and real-world studies, belimumab reduces disease activity and flares, enables glucocorticoid tapering, and slows organ damage accrual. In LN, it improves renal outcomes and reduces the risk of kidney-related events. Collectively, these findings support belimumab as a disease-modifying therapy in SLE. Further research is needed to refine patient selection and optimize treatment sequencing and combination strategies.

Schlagwörter

Stichwörter der Autor:innen

B-cell subsetsBAFF inhibitionbelimumabdisease modificationsystemic lupus erythematosus

Autor:innen und Institutionen

  • Department of Nephrology and Renal Transplantation, Hospital Clinic, 08036 Barcelona, Spain.
  • Reference Center for Complex Glomerular Diseases, Spanish Health System (CSUR), 08036 Barcelona, Spain.
  • Department of Medicine, University of Barcelona, 08036 Barcelona, Spain.
  • Institut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), 08036 Barcelona, Spain.
  • Department of Autoimmune Diseases, Hospital Clinic, 08036 Barcelona, Spain.
  • Reference Centre for Systemic Autoimmune Diseases of the Catalan (XUEC), Spanish Health System (CSUR), 08036 Barcelona, Spain.

ORCID-Profile: Marc Xipell, María Cecilia Garbarino, Carla Bastida, Ignasi Rodríguez-Pintó, Jose A Gómez-Puerta, Gerard Espinosa, Luis F Quintana, Ricard Cervera

Zitieren

APA

Xipell, M., Garbarino, M. C., Serrano Del Castillo, C., Morantes, L., Bastida, C., Rodríguez-Pintó, I., Gómez-Puerta, J. A., Espinosa, G., Quintana, L. F., & Cervera, R. (2026). Belimumab in Systemic Lupus Erythematosus: From B-Cell Biology to Disease Modification. Journal of Clinical Medicine, 15(8), 3173. https://doi.org/10.3390/jcm15083173

Vancouver

Xipell M, Garbarino MC, Serrano Del Castillo C, Morantes L, Bastida C, Rodríguez-Pintó I, et al. Belimumab in Systemic Lupus Erythematosus: From B-Cell Biology to Disease Modification. Journal of Clinical Medicine. 2026;15(8):3173. doi:10.3390/jcm15083173

BibTeX
@article{Xipell2026,
  author = {Xipell, Marc and Garbarino, María Cecilia and Serrano Del Castillo, Cristina and Morantes, Laura and Bastida, Carla and Rodríguez-Pintó, Ignasi and Gómez-Puerta, Jose A and Espinosa, Gerard and Quintana, Luis F and Cervera, Ricard},
  title = {Belimumab in Systemic Lupus Erythematosus: From B-Cell Biology to Disease Modification},
  journal = {Journal of Clinical Medicine},
  year = {2026},
  volume = {15},
  number = {8},
  pages = {3173},
  doi = {10.3390/jcm15083173}
}
Kostenlos starten →